These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25089830)

  • 1. Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin.
    Nilvebrant J; Åstrand M; Georgieva-Kotseva M; Björnmalm M; Löfblom J; Hober S
    PLoS One; 2014; 9(8):e103094. PubMed ID: 25089830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering bispecificity into a single albumin-binding domain.
    Nilvebrant J; Alm T; Hober S; Löfblom J
    PLoS One; 2011; 6(10):e25791. PubMed ID: 21991353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
    Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
    Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.
    Riccio G; Ricardo AR; Passariello M; Saraiva K; Rubino V; Cunnah P; Mertens N; De Lorenzo C
    J Immunother; 2019 Jan; 42(1):1-10. PubMed ID: 30520849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.
    Larimer BM; Thomas WD; Smith GP; Deutscher SL
    Mol Imaging Biol; 2014 Aug; 16(4):449-58. PubMed ID: 24550054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific Antibodies for IFN-β Delivery to ErbB2
    Rybchenko VS; Panina AA; Aliev TK; Solopova ON; Balabashin DS; Novoseletsky VN; Dolgikh DA; Sveshnikov PG; Kirpichnikov MP
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative binding analysis of monoclonal antibodies against native and mutant type in ErbB2 receptor: a theoretical modeling approach.
    Rajasekaran R; Rao S
    Curr Pharm Biotechnol; 2009 Nov; 10(7):701-8. PubMed ID: 19751177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redirecting adenoviruses to tumour cells using therapeutic antibodies: Generation of a versatile human bispecific adaptor.
    Vasiljevic S; Beale EV; Bonomelli C; Easthope IS; Pritchard LK; Seabright GE; Caputo AT; Scanlan CN; Dalziel M; Crispin M
    Mol Immunol; 2015 Dec; 68(2 Pt A):234-43. PubMed ID: 26391350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
    Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
    Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis.
    Franco-Gonzalez JF; Cruz VL; Ramos J; Martínez-Salazar J
    J Mol Model; 2013 Mar; 19(3):1227-36. PubMed ID: 23160933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
    Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
    BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.
    Shukla GS; Krag DN
    Comb Chem High Throughput Screen; 2010 Jan; 13(1):75-87. PubMed ID: 20214576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
    Xie Z; Shi M; Feng J; Yu M; Sun Y; Shen B; Guo N
    Biochem Biophys Res Commun; 2003 Nov; 311(2):307-12. PubMed ID: 14592414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.
    Mazor Y; Sachsenmeier KF; Yang C; Hansen A; Filderman J; Mulgrew K; Wu H; Dall'Acqua WF
    Sci Rep; 2017 Jan; 7():40098. PubMed ID: 28067257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.